Practical articles organized by catalog use, documentation review, custom planning, and research procurement.
Choose a category to narrow the published guidance.
13 articles
No pharmaceutical company has pursued the TB-500 fragment as a drug candidate. RegeneRx used full-length Tβ4 throughout its clinical development. This article explains the scientific logic behind that choice.
Read guidance →
The Paradigm Peptides case did not happen suddenly. From the start of sales in 2019 to the sentencing in 2026, it went through warning letters, product seizures, a business shutdown, and guilty pleas. This article lays out the full timeline.
Read guidance →
ONPEPS has not identified a specific harm tied to CJC-1295 or Ipamorelin, but product problems are documented: black-market contents that do not match labels, and forged COAs. This article reviews gray-market risks.
Read guidance →
This article answers the 10 most common questions about GLOW peptide in a Q&A format, covering composition, effects, dosing, reconstitution, side effects, legality, and WADA status.
Read guidance →
Cagrilintide monotherapy lost 11.5% at 68 weeks; combined with semaglutide it reached 20.4%. Tirzepatide reached 20.9% at 72 weeks, and retatrutide 24.2% at 48 weeks. These numbers come from different trials and cannot be compared directly. This article lists each compound's target, regulatory status, best published weight-loss figure and dosing frequency.
Read guidance →
Retatrutide is currently the most-searched peptide in the U.S., with search interest about 10× that of BPC-157 over the past three months. This article explains three reasons: Phase III data, lack of legal access, and Lilly’s lawsuits.
Read guidance →
Many peptides show promise in early research, but large-scale clinical data is severely lacking. This article explains the causes and implications of this evidence gap, and why it matters more than online hype.
Read guidance →
The safety of BPC-157 is one of the most hotly debated topics between peptide users and skeptics. This article explains animal toxicity studies, the WADA ban, and why human safety data remains insufficient.
Read guidance →
The global food industry generates huge amounts of waste every year, and hidden within it are high-value peptides. This article explains how peptides are extracted from plant, animal, and marine byproducts, and the potential and challenges of this direction in the circular economy.
Read guidance →
A practical checklist for identifying a catalog record and giving the review team enough information to answer accurately.
Read guidance →
Understand the difference between a catalog statement, a mapped historical file, and documentation for the material currently being quoted.
Read guidance →
The sequence, modification, purity, quantity, analytical, destination, and timing details that make a custom request reviewable.
Read guidance →
A controlled way to compare identity, specification, evidence, destination requirements, and lead time before a purchase decision.
Read guidance →